Drugs / TIL 1383I TCR transduced T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02870244 | Feb 2015 → Sep 2028 expected | melanoma | Loyola University | Recruiting | No outcome recorded |
| Phase 1 | NCT01586403 | Jul 2012 → Sep 2028 expected | melanoma | Loyola University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIL 1383I TCR transduced T cells | “Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2.” NCT01586403 ↗1“Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.” NCT02870244 ↗ |
| Known as | TIL 13831 TCR transduced T cells | “Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.” NCT02870244 ↗ |
| Modality | Cell therapy | “autologous bulk TIL 1383I TCR transduced T cells” NCT01586403 ↗ |